Traders purchased shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Friday. $222.43 million flowed into the stock on the tick-up and $114.14 million flowed out of the stock on the tick-down, for a money net flow of $108.29 million into the stock. Of all companies tracked, Johnson & Johnson had the 2nd highest net in-flow for the day. Johnson & Johnson traded down ($0.12) for the day and closed at $125.03

Several research analysts recently issued reports on JNJ shares. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 20th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 6th. Wells Fargo & Co. reaffirmed a “buy” rating and set a $115.00 target price on shares of Johnson & Johnson in a research report on Thursday, April 7th. Finally, Argus upped their target price on Johnson & Johnson from $116.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, April 20th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and ten have issued a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average price target of $117.04.

The company’s 50 day moving average is $119.61 and its 200-day moving average is $110.34. The company has a market capitalization of $343.91 billion and a PE ratio of 23.30.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.06. The company earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Equities analysts forecast that Johnson & Johnson will post $6.69 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 19th. Shareholders of record on Friday, August 5th will be given a dividend of $0.29 per share. This represents a $1.16 annualized dividend and a yield of 0.93%.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,957 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $114.77, for a total transaction of $454,144.89. Following the transaction, the chief accounting officer now owns 29,682 shares in the company, valued at approximately $3,406,603.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Gary J. Pruden sold 9,735 shares of the business’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total value of $1,129,552.05. Following the transaction, the vice president now owns 43,630 shares in the company, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. Coconut Grove Bank acquired a new position in Johnson & Johnson during the fourth quarter valued at about $1,353,000. Peoples Financial Services CORP. boosted its position in Johnson & Johnson by 1.1% in the fourth quarter. Peoples Financial Services CORP. now owns 32,943 shares of the company’s stock valued at $3,384,000 after buying an additional 367 shares during the last quarter. Yorktown Management & Research Co Inc boosted its position in Johnson & Johnson by 91.8% in the fourth quarter. Yorktown Management & Research Co Inc now owns 21,100 shares of the company’s stock valued at $2,167,000 after buying an additional 10,100 shares during the last quarter. Clean Yield Group boosted its position in Johnson & Johnson by 3.2% in the fourth quarter. Clean Yield Group now owns 58,316 shares of the company’s stock valued at $5,760,000 after buying an additional 1,800 shares during the last quarter. Finally, Morgan Dempsey Capital Management LLC boosted its position in Johnson & Johnson by 19.0% in the fourth quarter. Morgan Dempsey Capital Management LLC now owns 14,657 shares of the company’s stock valued at $1,506,000 after buying an additional 2,341 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.